Answers are grounded in this paper and cite their sources.
Case report reveals marked symptom reduction following intranasal esketamine in comorbid treatment-resistant illness, highlighting potential utility for dual obsessive and depressive disorders.
Background: Evidence for repeated intranasal esketamine in obsessive–compulsive disorder (OCD) remains preliminary, particularly when OCD co-occurs with treatment-resistant depression (TRD). Methods: We report a 58-year-old woman treated with intranasal esketamine in routine clinical care for TRD; change in obsessive–compulsive symptoms was followed as a secondary observational outcome. Her history aligned with the eligibility framework of a 2026 prospective intranasal esketamine series: primary Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) OCD, baseline Yale–Brown Obsessive Compulsive Scale (Y-BOCS) score of 33, a comorbid major depressive episode with a Montgomery–Åsberg Depression Rating Scale (MADRS) score of 38, sequential inadequate response to two high-dose selective serotonin reuptake inhibitor (SSRI) trials, clomipramine 250 mg/day for 6 months, eight cognitive-behavioral therapy (CBT) sessions incorporating exposure and response prevention (ERP), and brexpiprazole augmentation. The CBT/ERP course was time-limited and did not overlap with esketamine. Esketamine was administered at 56 mg initially and 84 mg thereafter, twice weekly for 4 weeks, weekly in month 2, and every 2 weeks during months 3–6. Results: MADRS/Y-BOCS scores were 23/18 at month 1, 19/15 at month 3, and 17/14 at month 6, corresponding to reductions of 55.3% and 57.6%. The OCD response threshold was met from month 1 and the depression response threshold from month 3. Adverse effects were transient and required no medical intervention or treatment discontinuation. Conclusions: During 6 months of routine-care intranasal esketamine augmentation for TRD, obsessive–compulsive improvement accompanied antidepressant improvement. The observation is hypothesis-generating and cannot distinguish a direct anti-obsessional effect from improvement related to depression, ongoing oral treatment, repeated clinical contact, or other nonspecific factors.
No takes yet. Share an insight, caveat, or question.
Barlattani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: